Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 9.7% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (TNDM) is a company specializing in advanced automated insulin delivery systems, known for products like the Tandem Mobi and t:slim X2 insulin pumps. The company recently reported strong Q1 2026 financial results, exceeding revenue expectations and showcasing growth in pump shipments and sales.

Why is Tandem Diabetes Care, Inc. going down?

TNDM stock is down 9.7% on May 8, 2026 14:21

• Despite strong Q1 2026 financial results and strategic advancements, Tandem Diabetes Care's stock experienced a bearish movement.
• Concerns about the company's transition to a pay-as-you-go pharmacy model may have led to the market's negative reaction, with analysts predicting a potential near-term revenue decline and impact on earnings per share.
• Investors could be cautious due to short-term challenges from the operational shift, despite the company's positive long-term outlook and innovations in diabetes technology.
• The bearish movement might also result from profit-taking actions following the stock's recent strong performance and analyst upgrades, prompting investors to reassess their Tandem Diabetes Care positions.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Tandem Diabetes Care Announces First Quarter 2026 Financial Results

Tandem Diabetes Care (Nasdaq: TNDM) reported strong Q1 2026 financial results, achieving record pump shipments and sales, along with a significant increase in gross margin. The company reaffirmed its full-year 2026 financial guidance and highlighted strategic advancements like the launch of a new reimbursement model and expanded Android compatibility for its Tandem Mobi system. These results demonstrate Tandem's commitment to innovation and growth in the diabetes technology market.

https://www.biospace.com/press-releases/tandem-diabetes-care-announces-first-quarter-2026-financial-results

Earnings Flash (TNDM) Tandem Diabetes Care, Inc. Reports Q1 Revenue $247.2M, vs. FactSet Est of $240.4M

Tandem Diabetes Care, Inc. reported its Q1 revenue reached $247.2 million, surpassing the FactSet estimate of $240.4 million. The company, which specializes in advanced automated insulin delivery systems like the Tandem Mobi and t:slim X2 insulin pumps, exceeded analyst expectations for its first-quarter performance. This financial update follows recent FDA clearances for their Control-IQ+ technology and several analyst upgrades.

https://www.marketscreener.com/news/earnings-flash-tndm-tandem-diabetes-care-inc-reports-q1-revenue-247-2m-vs-factset-est-of-240-ce7f5bdada8cf42c

Tandem Diabetes (NASDAQ: TNDM) lifts Q1 2026 margins and reaffirms outlook

Tandem Diabetes Care reported improved Q1 2026 results, with sales increasing 5% to $247.2 million and gross margin reaching 55%. The company significantly narrowed its GAAP operating loss and net loss, while adjusted EBITDA turned positive at $2.7 million. Tandem Diabetes reaffirmed its full-year 2026 financial guidance, anticipating sales between $1.065 billion and $1.085 billion, with continued margin expansion.

https://www.stocktitan.net/sec-filings/TNDM/8-k-tandem-diabetes-care-inc-reports-material-event-bc24634375cd.html

Tandem Diabetes faces earnings test as pay-as-you-go shift weighs

Tandem Diabetes Care Inc. is set to report first-quarter earnings, with investors focused on the operational impact of its transition to a pay-as-you-go pharmacy model. Analysts expect a near-term revenue decline and loss per share due to this shift, which is projected to create headwinds in 2026, despite a long-term positive outlook. Key factors investors will monitor include execution speed of the transition, new prescription growth for the Mobi system, and progress towards targeted gross and EBITDA margins.

https://m.investing.com/news/earnings/tandem-diabetes-faces-earnings-test-as-payasyougo-shift-weighs-93CH-4668968?ampMode=1

Tandem Diabetes Care upgraded by Robert W. Baird with a new price target

Tandem Diabetes Care (TNDM) has received an upgrade from Robert W. Baird, including a new price target. This insight, provided by Quantisnow, highlights recent analyst ratings and SEC filings for the company. Quantisnow is a platform that offers real-time market data to retail investors.

https://www.quantisnow.com/insight/tandem-diabetes-care-upgraded-by-robert-w-baird-with-a-new-price-target-6317415

Trending Today

Aave ($AAVE) Crypto Forecast: Up 5.2% Today

ZCash ($ZEC) Crypto Forecast: Up 6.0% Today

Power Integrations Inc. ($POWI) Stock Forecast: Down 7.2% Today

CDW Corporation ($CDW) Stock Forecast: Down 5.2% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 8.0% Today

Microchip Technology Incorporated ($MCHP) Stock Forecast: Down 5.1% Today

Sunrun Inc. ($RUN) Stock Forecast: Up 5.3% Today

BorgWarner Inc. ($BWA) Stock Forecast: Up 5.1% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Up 7.6% Today

The Trade Desk Inc ($TTD) Stock Forecast: Down 5.1% Today

Tandem Diabetes Care, Inc. Price History

21.03.2026 - TNDM Stock was down 5.2%

• Tandem Diabetes Care (TNDM) stock saw a decrease, despite TD Cowen boosting its price target to $28 and maintaining a Buy rating. The decline could be linked to investors taking profits after a period of price appreciation.
• The Chief Operating Officer of the company exercised restricted stock units (RSUs), with some shares held back for taxes. This action may have added selling pressure on the stock as more shares became available in the market.
• Although there was excitement surrounding the upcoming launch of the Mobi Tubeless product and a new pay-as-you-go program, these factors might not have been enough to counterbalance the short-term selling pressures that led to the observed decrease in stock value.

30.03.2026 - TNDM Stock was up 6.0%

• Tandem Diabetes Care disclosed upcoming conference appearances at two notable investor conferences, hinting at positive prospects and potentially exciting updates for investors.
• The FDA clearance for Tandem's Control-IQ+ automated insulin delivery technology for pregnancy in Type 1 Diabetes may have increased investor confidence in the company's innovative products and market potential.
• Vanguard Portfolio Management's substantial investment in Tandem Diabetes Care underscores investor interest and confidence in the company's future growth prospects.
• The overview of Tandem's market opportunity, dedication to innovation, and emphasis on commercial transformation likely contributed to the market's bullish trend as investors recognize the company's strong position in the global diabetes market.

30.03.2026 - TNDM Stock was up 7.6%

• Tandem Diabetes Care's stock experienced a strong bullish movement today.
• The bullish trend could be attributed to positive market sentiment driven by an increased price target for TNDM, highlighting the company's new pay-as-you-go program and Mobi Tubeless product as drivers for future revenue growth.
• Additionally, the FDA clearance for Tandem's Control-IQ+ automated insulin delivery technology for pregnancy in Type 1 Diabetes could have further boosted investor confidence in the company's innovative products and market potential.
• Significant stake in Tandem Diabetes Care Inc. by Vanguard Portfolio Management could also indicate institutional investor confidence in the company's long-term growth prospects.

01.04.2026 - TNDM Stock was up 7.7%

• Tandem Diabetes Care (TNDM) experienced a strong bullish movement recently.
• Vanguard Capital Management's significant passive institutional investment of over 3.5 million shares in TNDM may have instilled confidence in other investors, contributing to the bullish trend.
• The raised price target by TD Cowen and the positive outlook on TNDM's new products driving future revenue growth likely attracted more investors to the stock.
• The announcement of upcoming conference presentations by Tandem Diabetes Care could have also generated excitement and optimism among investors, further fueling the bullish momentum.

28.03.2026 - TNDM Stock was down 6.6%

• The decrease in Tandem Diabetes Care's stock today may be due to profit-taking by investors following a period of positive momentum.
• Despite the favorable FDA clearance for the utilization of Control-IQ+ technology in pregnancy, the market's reaction might have been adverse as a result of already high expectations priced into the stock.
• The upgraded rating by Truist Securities and enthusiasm regarding the new pharmacy distributor model could have already been considered in the stock price, leading to a sell-off after the news.
• Investor concerns about the company's capacity to maintain growth and market presence in the competitive diabetes management sector may be contributing to a bearish outlook in the market.

28.03.2026 - TNDM Stock was down 5.5%

• The FDA clearance for Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy complicated by type 1 diabetes, while positive news, might have raised concerns about potential competition in the market leading to a bearish sentiment.
• Despite positive analyst upgrades from Truist Securities and Piper Sandler on Tandem's new pharmacy distributor model and strategy, the market may have reacted negatively due to profit-taking by investors after recent gains.
• Tandem Diabetes Care's strategic transformation initiatives outlined at the TD Cowen 46th Annual Health Care Conference could be seen as promising for the company's future growth, but the market may have interpreted them as long-term investments impacting short-term profitability, contributing to the bearish movement.
• Overall, the bearish movement in TNDM stock today could be a result of a combination of profit-taking, market competition concerns, and short-term impact of strategic transformations on profitability.

14.03.2026 - TNDM Stock was up 6.0%

• The surge in TNDM stock price could be attributed to the company being perceived as undervalued, with a GF Score of 74 indicating above-average potential for long-term returns.
• Maintaining a "Hold" rating and a target price of $22 might have provided investors with confidence in the current valuation of the stock.
• Positive sentiment from an AI analysis suggesting specific trading strategies and key support levels could have attracted more investors to TNDM.
• The overall bullish trend in the diabetes care market, with projected growth and technological advancements, might have positively impacted TNDM's stock price as it positions itself as a key player in the industry.

16.03.2026 - TNDM Stock was down 6.1%

• TNDM shares rose by 4.8% to $20.10, despite being undervalued, potentially prompting profit-taking by investors and contributing to the bearish trend.
• Mizuho Securities has maintained a "Hold" rating with a target price of $22, suggesting a neutral outlook that may not be driving significant positive momentum for the stock.
• Institutional trading strategies utilizing AI models could have resulted in selling pressure if recommended short positions were achieved.
• Anticipated growth in the diabetes care market until 2030 may have redirected investor attention towards other industry leaders, negatively impacting TNDM's stock performance in the short term.

08.04.2026 - TNDM Stock was down 9.7%

• Despite strong Q1 2026 financial results and strategic advancements, Tandem Diabetes Care's stock experienced a bearish movement.
• Concerns about the company's transition to a pay-as-you-go pharmacy model may have led to the market's negative reaction, with analysts predicting a potential near-term revenue decline and impact on earnings per share.
• Investors could be cautious due to short-term challenges from the operational shift, despite the company's positive long-term outlook and innovations in diabetes technology.
• The bearish movement might also result from profit-taking actions following the stock's recent strong performance and analyst upgrades, prompting investors to reassess their Tandem Diabetes Care positions.

04.04.2026 - TNDM Stock was down 5.0%

• A notable passive institutional investment by Vanguard Capital Management in Tandem Diabetes Care may have indicated lack of confidence in the company's future, influencing the bearish trend.
• Despite TD Cowen increasing TNDM's price target and maintaining a Buy rating, the market's negative reaction to the company's announcement of upcoming investor conference details might have led to market pessimism.
• Investors possibly engaged in profit-taking due to the anticipation of Tandem Diabetes Care's presentations at upcoming investor conferences, which could have driven down the stock price.
• Shifting market sentiment towards medical stocks priced below $30 could have impacted Tandem Diabetes Care's stock performance, notwithstanding positive forecasts for future revenue growth.

06.04.2026 - TNDM Stock was down 5.2%

• The FDA clearance for Tandem's Control-IQ+ technology for pregnant individuals with type 1 diabetes could have raised concerns among investors about potential regulatory and pricing pressures, leading to the bearish market movement.
• The disclosure of significant ownership stakes by institutional investors like Voya Financial and Vanguard Capital Management might have influenced market sentiment, contributing to the downward trend in TNDM stock.
• Despite TD Cowen raising Tandem Diabetes' price target and maintaining a Buy rating, the overall market reaction to the news about the pay-as-you-go program and Mobi Tubeless product may have been overshadowed by other factors, resulting in the bearish movement observed today.

06.04.2026 - TNDM Stock was down 6.0%

• Investor concerns about potential dilution of existing shares following an upsized private placement of convertible senior notes may have influenced the negative market sentiment.
• Despite the FDA clearance for Control-IQ+ technology for pregnant individuals with type 1 diabetes, worries about execution risks related to new distribution models and regulatory pressures could have outweighed the positive news.
• The disclosure of substantial ownership stakes by institutional investors such as Voya Financial and Vanguard Capital Management could have led to increased selling pressure as some investors may view this as a lack of confidence in TNDM's short-term prospects.
• Insights driven by pricing data and AI-generated trading strategies pointing out choppy conditions and diverging sentiment across different time frames might have exacerbated uncertainty and contributed to the stock's bearish movement today.